Cargando…
Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
BACKGROUND: Ph-positive leukemias are caused by the aberrant fusion of the BCR and ABL genes. Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to treat chronic myelogenous leukemia. Because Ph-positive acute lymphoblastic leukemia only responds tra...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2169263/ https://www.ncbi.nlm.nih.gov/pubmed/17958915 http://dx.doi.org/10.1186/1476-4598-6-67 |
_version_ | 1782144860568944640 |
---|---|
author | Kaur, Pavinder Feldhahn, Niklas Zhang, Bin Trageser, Daniel Müschen, Markus Pertz, Veerle Groffen, John Heisterkamp, Nora |
author_facet | Kaur, Pavinder Feldhahn, Niklas Zhang, Bin Trageser, Daniel Müschen, Markus Pertz, Veerle Groffen, John Heisterkamp, Nora |
author_sort | Kaur, Pavinder |
collection | PubMed |
description | BACKGROUND: Ph-positive leukemias are caused by the aberrant fusion of the BCR and ABL genes. Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to treat chronic myelogenous leukemia. Because Ph-positive acute lymphoblastic leukemia only responds transiently to imatinib therapy, we have used mouse models to test the efficacy of nilotinib against lymphoblastic leukemia caused by the P190 form of Bcr/Abl. RESULTS: After transplant of 10,000 highly malignant leukemic cells into compatible recipients, untreated mice succumbed to leukemia within 21 days, whereas mice treated with 75 mg/kg nilotinib survived significantly longer. We examined cells from mice that developed leukemia while under treatment for Bcr/Abl kinase domain point mutations but these were not detected. In addition, culture of such cells ex vivo showed that they were as sensitive as the parental cell line to nilotinib but that the presence of stromal support allowed resistant cells to grow out. Nilotinib also exhibited impressive anti-leukemia activity in P190 Bcr/Abl transgenic mice that had developed overt leukemia/lymphoma masses and that otherwise would have been expected to die within 7 days. Visible lymphoma masses disappeared within six days of treatment and leukemic cell numbers in peripheral blood were significantly reduced. Treated mice survived more than 30 days. CONCLUSION: These results show that nilotinib has very impressive anti-leukemia activity but that lymphoblastic leukemia cells can become unresponsive to it both in vitro and in vivo through mechanisms that appear to be Bcr/Abl independent. |
format | Text |
id | pubmed-2169263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-21692632007-12-29 Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia Kaur, Pavinder Feldhahn, Niklas Zhang, Bin Trageser, Daniel Müschen, Markus Pertz, Veerle Groffen, John Heisterkamp, Nora Mol Cancer Research BACKGROUND: Ph-positive leukemias are caused by the aberrant fusion of the BCR and ABL genes. Nilotinib is a selective Bcr/Abl tyrosine kinase inhibitor related to imatinib, which is widely used to treat chronic myelogenous leukemia. Because Ph-positive acute lymphoblastic leukemia only responds transiently to imatinib therapy, we have used mouse models to test the efficacy of nilotinib against lymphoblastic leukemia caused by the P190 form of Bcr/Abl. RESULTS: After transplant of 10,000 highly malignant leukemic cells into compatible recipients, untreated mice succumbed to leukemia within 21 days, whereas mice treated with 75 mg/kg nilotinib survived significantly longer. We examined cells from mice that developed leukemia while under treatment for Bcr/Abl kinase domain point mutations but these were not detected. In addition, culture of such cells ex vivo showed that they were as sensitive as the parental cell line to nilotinib but that the presence of stromal support allowed resistant cells to grow out. Nilotinib also exhibited impressive anti-leukemia activity in P190 Bcr/Abl transgenic mice that had developed overt leukemia/lymphoma masses and that otherwise would have been expected to die within 7 days. Visible lymphoma masses disappeared within six days of treatment and leukemic cell numbers in peripheral blood were significantly reduced. Treated mice survived more than 30 days. CONCLUSION: These results show that nilotinib has very impressive anti-leukemia activity but that lymphoblastic leukemia cells can become unresponsive to it both in vitro and in vivo through mechanisms that appear to be Bcr/Abl independent. BioMed Central 2007-10-25 /pmc/articles/PMC2169263/ /pubmed/17958915 http://dx.doi.org/10.1186/1476-4598-6-67 Text en Copyright © 2007 Kaur et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Kaur, Pavinder Feldhahn, Niklas Zhang, Bin Trageser, Daniel Müschen, Markus Pertz, Veerle Groffen, John Heisterkamp, Nora Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia |
title | Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia |
title_full | Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia |
title_fullStr | Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia |
title_full_unstemmed | Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia |
title_short | Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia |
title_sort | nilotinib treatment in mouse models of p190 bcr/abl lymphoblastic leukemia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2169263/ https://www.ncbi.nlm.nih.gov/pubmed/17958915 http://dx.doi.org/10.1186/1476-4598-6-67 |
work_keys_str_mv | AT kaurpavinder nilotinibtreatmentinmousemodelsofp190bcrabllymphoblasticleukemia AT feldhahnniklas nilotinibtreatmentinmousemodelsofp190bcrabllymphoblasticleukemia AT zhangbin nilotinibtreatmentinmousemodelsofp190bcrabllymphoblasticleukemia AT trageserdaniel nilotinibtreatmentinmousemodelsofp190bcrabllymphoblasticleukemia AT muschenmarkus nilotinibtreatmentinmousemodelsofp190bcrabllymphoblasticleukemia AT pertzveerle nilotinibtreatmentinmousemodelsofp190bcrabllymphoblasticleukemia AT groffenjohn nilotinibtreatmentinmousemodelsofp190bcrabllymphoblasticleukemia AT heisterkampnora nilotinibtreatmentinmousemodelsofp190bcrabllymphoblasticleukemia |